Hospira, Inc. v. Amneal Pharmaceuticals LLC, C.A. No. 15-697 – RGA, May 25, 2016.

Andrews, J. Claim construction opinion issues regarding four terms from four patents.

The disputed technology relates to dexmedetomidine. The following terms were considered:

  1. “dexmedetomidine”
  2. “no more than about 2% decrease in the concentration of dexmedetomidine”
  3. “critically ill”
  4. “intensive care unit”